Genetic stability (in vivo) of the attenuated oral rabies virus vaccine SAD B19

Microbiology and Immunology

Volumn 53, Issue 1, 2009, Pages 16-21

  Beckert, Aline ^a   Geue, Lutz ^a   Vos, Ad ^b   Neubert, Andreas ^b   Freuling, Conrad ^a   Müller, Thomas ^a  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b IDT Biologika GmbH   (Germany)

Author keywords

Genetic stability; Oral vaccine; Rabies

Indexed keywords

LIVE VACCINE; RABIES VACCINE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; FOX; GENOMIC INSTABILITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RABIES VIRUS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS GENE; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; CELL LINE; GENETICS; HAMSTER; MOLECULAR GENETICS; MUTATION; ORAL DRUG ADMINISTRATION; PATHOGENICITY; RABIES; VIROLOGY; VIRULENCE; VIRUS CULTURE;

CANIDAE; MUS; RABIES VIRUS;

ADMINISTRATION, ORAL; ANIMALS; BASE SEQUENCE; CELL LINE; CRICETINAE; FOXES; GENOMIC INSTABILITY; MICE; MOLECULAR SEQUENCE DATA; MUTATION; RABIES; RABIES VACCINES; RABIES VIRUS; SERIAL PASSAGE; VACCINES, ATTENUATED; VIRAL PROTEINS; VIRULENCE;

EID: 61749084452     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2008.00085.x     Document Type: Article

References (30)

1. Steck F.,Wandeler A.I., Bischel P., Capt S., Häfliger U., Schneider L.G. (1982) Oral immunization of foxes against rabies. Laboratory and field studies. Comp Immun Microbiol Infect Dis 5: 165-71.
2. Dietzschold B., Faber M., Schnell M.J. (2003) New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2: 399-406.
3. Wandeler A.I. (1988) Control of wildlife rabies. In: Campbell J.B., Charlton K.M., eds. Rabies. Boston: Kluwer Academic Publications, pp. 365-80.
4. Rupprecht C.E., Blass L., Smith K., Orciari L.A., Niezgoda M., Whitfield S.G. et al. (2001). Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 345: 582-6.
5. Müller T., Geue L., Selhorst T., Frost J., Bunzenthal C., Zimmer K. et al. (2005) Vaccine associated rabies cases in Germany and Austria. XVI International Conference Rabies in the Americas, 16-21 October, 2005; Ottawa, Canada, p. 44.
6. Fehlner-Gardiner C., Nadin-Davis S., Armstrong J., Muldoon F., Bachmann P.,Wandeler A. (2008) ERA vaccine-derived cases of rabies in wildlife and domestic animals in Ontario, Canada, 1989-2004. J Wildl Dis 44: 71-85.
7. EMEA/CVMP. (2004) Guidline on target animal safety: Examination of live veterinary vaccines in target animals for absence of reversion to virulence. CVMP/VICH/1052/2004-consultation. London: EMEA.
8. Arai Y.T. (1985) Virulence of chick embryo fibroblast-passaged flury HEP rabies virus and its revertants in mice. Microbiol Immunol 29: 811-23.
9. Vos A., Neubert A., Aylan O., Schuster P., Pommerening E., Müller T. et al. (1999) An update on safety studies of SAD B19 rabies virus vaccine in target and non-target species. Epidemiol Infect 123: 165-75.
10. Geue L., Schares S., Schnick C., Kliemt J., Beckert A., Freuling C. et al. (2008) Genetic characterisation of attenuated SAD rabies virus strains used for oral vaccination of wildlife. Vaccine doi: 10.1016/j.vaccine. 2008.04.007.
11. Conzelmann K.K., Cox J.H., Schneider L.G., Thiel H.J. (1990) Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virol 175: 485-99.
12. Kassis R., Larrous F., Estaquier J., Bourhy H. (2004) Lyssavirus matrix protein induces apoptosis by a TRIAL-dependent mechanism involving caspase-8 activities. J Virol 78: 6543-55.
13. Mebatsion T.,Weiland F., Conzelmann K.K. (1999) Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J Virol 73: 242-50
14. Brzozka K., Finke S., Conzelmann K.K. (2005) Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J Virol 79: 7673-81.
15. Marston D.A., McElhinney L.M., Johnson N., Müller T., Conzelmann K.K., Tordo N. et al. (2007) Comparative analysis of the full genome sequence of European bat lyssavirus type 1 and type 2 with other lyssaviruses and evidence for a conserved transcription termination and polyadenylation motif in the G-L 3′ non-translated region. J Gen Virol 88: 1302-14.
16. Cello J., Paul A.V.,Wimmer E. (2000) Chemical synthesis of poliovirus cDNA: Generation of infectious virus in the absence of natural template. Science 297: 1016-18.
17. Burns C.C., Shaw J., Campagnoli R., Jorba J., Vincent A., Quay J. et al. (2006) Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J Virol 80: 3259-72.
18. Kissi B., Badrane H., Audry L., Lavenu A., Tordo N., Brahimi M. et al. (1999) Dynamics of rabies virus quasispecies during serial passages in heterologous hosts. J Gen Virol 80: 2041-50.
19. Eigen M. (1996) On the nature of virus quasispecies. Trends Microbiol 4: 216-18.
20. Domingo E. (2002) Quasispecies theory in virology. J Virol 76: 463-65.
21. Benmansour A., Brahimi M., Tuffereau C., Coulon P., Lafay F., Flamand A. (1992) Rapid sequence evolution of street rabies glycoprotein is related to the highly heterogeneous nature of the viral population. Virol 187: 33-45.
22. Morimoto K., Hooper D.C., Carbaugh H., Fu Z.F., Koprowski H., Dietzschold B. (1998) Rabies virus quasispecies: implications for pathogenesis. Proc Natl Acad Sci USA 95: 3152-6.
23. Dietzschold B.,WunnerW.H.,Wiktor T.J., Lopes D., Lafon M., Smith C.L. et al. (1983) Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci USA 80: 70-4.
24. Lafay F., Benejean J., Tuffereau C., Flamand A., Coulon P. (1994) Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SAD Bern. Vaccine 12: 317-20.
25. Takayama-Ito M., Inoue K., Shoji Y., Inoue S., Iijima T., Sakai T. et al. (2006) A highly attenuated rabies virus HEP-Flury strain reverts to virulent by single amino acid substitution to arginine at position 333 in glycoprotein. Virus Res 119: 208-15.
26. Dietzschold M.L., Faber M., Mattis J.A., Pak K.Y., Schnell M., Dietzschold B. (2004) In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. Vaccine 23: 518-24.
27. Faber M., Faber M.L., Papaneri A., Bette M.,Weihe E., Dietzschold B. et al. (2005) A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol 79: 14 141-8.
28. Ito N., Takayama M., Yamada K., Sugiyama M., Minamoto N. (2001) Rescue of rabies virus from clonal cDNA and identification of the pathogenicity-related gene: glycoprotein gene is associated with virulence for adult mice. J Virol 75: 9121-8.
29. Shimizu K., Ito N., Mita T., Yamada K., Hosokawa-Muto J., Sugiyama M. et al. (2007) Involvement of nucleoprotein, phosphoprotein, and matrix protein genes of rabies virus in virulence for adult mice. Virus Res 123: 154-60.
30. Ito N., Sugiyama M., Yamada K., Shimizu K., Takayama-Ito M., Hosokawa J. et al. (2005) Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol Immunol 49: 971-9.